[CAS NO. 90417-38-2] NU1025
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [90417-38-2]
Store
Catalog
SLK-S7730
Brand
Selleck
CAS
90417-38-2
DESCRIPTION [90417-38-2]
Overview
| MDL | MFCD00942555 |
|---|---|
| Molecular Weight | 176.17 |
| Molecular Formula | C9H8N2O2 |
| SMILES | O=C1C=2C(NC(C)=N1)=C(O)C=CC2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6763 mL | 28.3817 mL | 56.7634 mL |
| 5 mM | 1.1353 mL | 5.6763 mL | 11.3527 mL |
| 10 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL |
| 50 mM | 0.1135 mL | 0.5676 mL | 1.1353 mL |
Description
NU1025 (NSC 696807) is a potent inhibitor with of 400 nM.
Targets
| PARP [1] |
| 400 nM |
In vitro
NU1025 (0.2 mM) treatment attenuates HO induced cytotoxicity. NU1025 per se does not have any effect on cell viability. NU1025 pretreatment significantly increases cell viability (82.59 ?4.67%) in SIN-1 (0.8 mM) exposed cells. NU1025 has no detectable effect on the proliferation of D54 and U251 cells. Treatment with NU1025 markedly inhibits the enhanced activation of PARP-1 induced by TPT and RT treatment. No DNA strand breakage is detected following exposure to 200 µM NU1025 alone.
In vivo
Treatment with NU1025 (1 and 3 mg/kg) reduces the infarction to 25% and 45% versus vehicle treated rats, respectively. NU1025 (1 and 3 mg/kg) treatment significantly reduces edema volume. NU1025 also produces significant improvement in neurological deficits.
References
Synonyms
4(3H)-Quinazolinone, 8-hydroxy-2-methyl-
4(1H)-Quinazolinone, 8-hydroxy-2-methyl-
8-Hydroxy-2-methyl-4(3H)-quinazolinone
Nu 1025
NSC 696807
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.